Skip to main content
. Author manuscript; available in PMC: 2014 Aug 15.
Published in final edited form as: J Immunol. 2013 Jul 12;191(4):2009–2017. doi: 10.4049/jimmunol.1301317

Figure 6. T regulatory cell depletion in combination with chemotherapy extends survival.

Figure 6

Percent survival of CC10-TAg mice treated with control IgG or αCD25 mAb as monotherapy, or in combination with 50 mg/kg carboplatin (CBDCA). Dosing strategy is shown above the survival graph. Mice received control IgG or αCD25 mAb from 8 weeks of age until end-stage determined by 15% weight loss. Carboplatin was administered in 3 doses, 5 days apart, commencing at 13 weeks. Over 15 cohorts of mice were treated to obtain 10∓16 mice per group. p<0.05, control versus CBDCA alone; p<0.05, CBDCA alone versus αCD25/CBDCA.

HHS Vulnerability Disclosure